Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Retained Earnings (2021 - 2025)

Historic Retained Earnings for Indivior Pharmaceuticals (INDV) over the last 5 years, with Q3 2025 value amounting to -$346.0 million.

  • Indivior Pharmaceuticals' Retained Earnings fell 13233.64% to -$346.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$346.0 million, marking a year-over-year decrease of 13233.64%. This contributed to the annual value of -$443.0 million for FY2024, which is 5381.94% down from last year.
  • Indivior Pharmaceuticals' Retained Earnings amounted to -$346.0 million in Q3 2025, which was down 13233.64% from -$388.0 million recorded in Q2 2025.
  • Indivior Pharmaceuticals' 5-year Retained Earnings high stood at $1.4 billion for Q4 2021, and its period low was -$443.0 million during Q4 2024.
  • In the last 5 years, Indivior Pharmaceuticals' Retained Earnings had a median value of -$13.0 million in 2023 and averaged $433.4 million.
  • As far as peak fluctuations go, Indivior Pharmaceuticals' Retained Earnings surged by 833076.92% in 2024, and later plummeted by 13451.96% in 2025.
  • Quarter analysis of 5 years shows Indivior Pharmaceuticals' Retained Earnings stood at $1.4 billion in 2021, then dropped by 9.39% to $1.3 billion in 2022, then crashed by 122.1% to -$288.0 million in 2023, then plummeted by 53.82% to -$443.0 million in 2024, then rose by 21.9% to -$346.0 million in 2025.
  • Its Retained Earnings stands at -$346.0 million for Q3 2025, versus -$388.0 million for Q2 2025 and -$406.0 million for Q1 2025.